Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Dr. Reddy’s Laboratories Ltd ADR is a drug manufacturers-specialty & generic business based in the US. DrReddy’s Laboratories Ltd ADR shares (RDY) are listed on the NYSE and all prices are listed in US Dollars.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $55.84 |
|---|---|
| 52-week range | $47.88 - $75.16 |
| 50-day moving average | $53.90 |
| 200-day moving average | $58.75 |
| Wall St. target price | $64.80 |
| PE ratio | 30.776 |
| Dividend yield | $30 (0.63%) |
| Earnings per share (TTM) | $1.82 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $55.84 from 2022-07-01
| 1 week (2022-06-24) | -0.14% |
|---|---|
| 1 month (2022-06-02) | 55.84 |
| 3 months (2022-04-01) | 0.04% |
| 6 months (2021-12-31) | -14.63% |
| 1 year (2021-07-02) | -25.83% |
|---|---|
| 2 years (2020-07-02) | 5.60% |
| 3 years (2019-07-02) | 48.12% |
| 5 years (2017-06-30) | 32.51% |
Valuing DrReddy’s Laboratories Ltd ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of DrReddy’s Laboratories Ltd ADR's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
DrReddy’s Laboratories Ltd ADR's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 31x. In other words, DrReddy’s Laboratories Ltd ADR shares trade at around 31x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
DrReddy’s Laboratories Ltd ADR's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.1627. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into DrReddy’s Laboratories Ltd ADR's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
DrReddy’s Laboratories Ltd ADR's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $48.9 billion.
The EBITDA is a measure of a DrReddy’s Laboratories Ltd ADR's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $214.4 billion |
|---|---|
| Operating margin TTM | 17.28% |
| Gross profit TTM | $113.8 billion |
| Return on assets TTM | 8.24% |
| Return on equity TTM | 12.96% |
| Profit margin | 10.99% |
| Book value | $1,149.69 |
| Market capitalisation | $9.3 billion |
TTM: trailing 12 months
Dividend payout ratio: 38.43% of net profits
Recently DrReddy’s Laboratories Ltd ADR has paid out, on average, around 38.43% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.63% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), DrReddy’s Laboratories Ltd ADR shareholders could enjoy a 0.63% return on their shares, in the form of dividend payments. In DrReddy’s Laboratories Ltd ADR's case, that would currently equate to about $30 per share.
While DrReddy’s Laboratories Ltd ADR's payout ratio might seem fairly standard, it's worth remembering that DrReddy’s Laboratories Ltd ADR may be investing much of the rest of its net profits in future growth.
DrReddy’s Laboratories Ltd ADR's most recent dividend payout was on 10 August 2021. The latest dividend was paid out to all shareholders who bought their shares by 7 July 2021 (the "ex-dividend date").
DrReddy’s Laboratories Ltd ADR's shares were split on a 2:1 basis on 6 September 2006. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your DrReddy’s Laboratories Ltd ADR shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for DrReddy’s Laboratories Ltd ADR shares which in turn could have impacted DrReddy’s Laboratories Ltd ADR's share price.
Over the last 12 months, DrReddy’s Laboratories Ltd ADR's shares have ranged in value from as little as $47.88 up to $75.1553. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while DrReddy’s Laboratories Ltd ADR's is 0.1778. This would suggest that DrReddy’s Laboratories Ltd ADR's shares are less volatile than average (for this exchange).
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.